COVID-19 vaccination in India: Clinical guidance for patients with dermatological diseases
Since the advent of COVID-19 vaccines, dermatologists have frequently come across patients, especially those receiving immunomodulatory drugs, who express concerns about the safety and efficacy of vaccines. In this review, we aim to provide guidelines to dermatologists with regard to the three COVID...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2021-01-01
|
| Series: | Clinical Dermatology Review |
| Subjects: | |
| Online Access: | http://www.cdriadvlkn.org/article.asp?issn=2542-551X;year=2021;volume=5;issue=2;spage=139;epage=143;aulast=Chathra |
| _version_ | 1818678083993993216 |
|---|---|
| author | Namitha Chathra Savitha Somaiah |
| author_facet | Namitha Chathra Savitha Somaiah |
| author_sort | Namitha Chathra |
| collection | DOAJ |
| description | Since the advent of COVID-19 vaccines, dermatologists have frequently come across patients, especially those receiving immunomodulatory drugs, who express concerns about the safety and efficacy of vaccines. In this review, we aim to provide guidelines to dermatologists with regard to the three COVID-19 vaccines licensed for use in India. All dermatology patients, even the ones on immunomodulatory drugs, need to be encouraged to take the vaccine. COVID-19 vaccines are not contraindicated in individuals afflicted with eczema; atopic dermatitis; psoriasis; vitiligo; lichen planus; urticaria; connective tissue disorders; and bacterial, mycobacterial, viral, or fungal infections. However, those who have been seriously ill requiring hospitalization are advised to wait for 4–8 weeks. For patients on immunomodulatory drugs, when the disease is stable, the drug may be withheld or dosage reduced for 1–2 weeks following vaccination. However, the vaccination may be given without any modification in the drug/biological. People with a history of anaphylaxis/urticaria can receive a COVID-19 vaccine with 30 min postvaccination observation period. Absolute contraindications include a history of immediate hypersensitivity to any component of the vaccination and hypersensitivity following first dose of vaccination. Patients who have received vaccination can undergo procedures such as skin biopsy, cautery, cryotherapy, lasers, chemical peels, excisions, biopsy, and hair transplantation; fillers may be scheduled 2 weeks before or after the vaccination. |
| first_indexed | 2024-12-17T09:09:38Z |
| format | Article |
| id | doaj.art-b667bfd513ee473da37d7c009cb99c48 |
| institution | Directory Open Access Journal |
| issn | 2542-551X 2542-5528 |
| language | English |
| last_indexed | 2024-12-17T09:09:38Z |
| publishDate | 2021-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Clinical Dermatology Review |
| spelling | doaj.art-b667bfd513ee473da37d7c009cb99c482022-12-21T21:55:18ZengWolters Kluwer Medknow PublicationsClinical Dermatology Review2542-551X2542-55282021-01-015213914310.4103/cdr.cdr_48_21COVID-19 vaccination in India: Clinical guidance for patients with dermatological diseasesNamitha ChathraSavitha SomaiahSince the advent of COVID-19 vaccines, dermatologists have frequently come across patients, especially those receiving immunomodulatory drugs, who express concerns about the safety and efficacy of vaccines. In this review, we aim to provide guidelines to dermatologists with regard to the three COVID-19 vaccines licensed for use in India. All dermatology patients, even the ones on immunomodulatory drugs, need to be encouraged to take the vaccine. COVID-19 vaccines are not contraindicated in individuals afflicted with eczema; atopic dermatitis; psoriasis; vitiligo; lichen planus; urticaria; connective tissue disorders; and bacterial, mycobacterial, viral, or fungal infections. However, those who have been seriously ill requiring hospitalization are advised to wait for 4–8 weeks. For patients on immunomodulatory drugs, when the disease is stable, the drug may be withheld or dosage reduced for 1–2 weeks following vaccination. However, the vaccination may be given without any modification in the drug/biological. People with a history of anaphylaxis/urticaria can receive a COVID-19 vaccine with 30 min postvaccination observation period. Absolute contraindications include a history of immediate hypersensitivity to any component of the vaccination and hypersensitivity following first dose of vaccination. Patients who have received vaccination can undergo procedures such as skin biopsy, cautery, cryotherapy, lasers, chemical peels, excisions, biopsy, and hair transplantation; fillers may be scheduled 2 weeks before or after the vaccination.http://www.cdriadvlkn.org/article.asp?issn=2542-551X;year=2021;volume=5;issue=2;spage=139;epage=143;aulast=Chathracovid-19 vaccinationimmunomodulatory drugsskin diseases |
| spellingShingle | Namitha Chathra Savitha Somaiah COVID-19 vaccination in India: Clinical guidance for patients with dermatological diseases Clinical Dermatology Review covid-19 vaccination immunomodulatory drugs skin diseases |
| title | COVID-19 vaccination in India: Clinical guidance for patients with dermatological diseases |
| title_full | COVID-19 vaccination in India: Clinical guidance for patients with dermatological diseases |
| title_fullStr | COVID-19 vaccination in India: Clinical guidance for patients with dermatological diseases |
| title_full_unstemmed | COVID-19 vaccination in India: Clinical guidance for patients with dermatological diseases |
| title_short | COVID-19 vaccination in India: Clinical guidance for patients with dermatological diseases |
| title_sort | covid 19 vaccination in india clinical guidance for patients with dermatological diseases |
| topic | covid-19 vaccination immunomodulatory drugs skin diseases |
| url | http://www.cdriadvlkn.org/article.asp?issn=2542-551X;year=2021;volume=5;issue=2;spage=139;epage=143;aulast=Chathra |
| work_keys_str_mv | AT namithachathra covid19vaccinationinindiaclinicalguidanceforpatientswithdermatologicaldiseases AT savithasomaiah covid19vaccinationinindiaclinicalguidanceforpatientswithdermatologicaldiseases |